Gilead Sciences Inc
NASDAQ:GILD
Gilead Sciences Inc
NASDAQ:GILD
Price:
65.42 USD
0.23%
Market Closed
Updated:
Apr 29, 2024
Gilead Sciences Inc
Cash from Operating Activities
|
Gilead Sciences Inc
Cash from Operating Activities Peer Comparison
Comparables:
ABBV
AMGN
MRNA
VRTX
REGN
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Operating Activities
$8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
10%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Operating Activities
$22.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
14%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Operating Activities
$8.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
3%
|
|
|
Moderna Inc
NASDAQ:MRNA
|
Cash from Operating Activities
-$3.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Operating Activities
$3.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Operating Activities
$4.6B
|
CAGR 3-Years
21%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
See Also
What is Gilead Sciences Inc's Cash from Operating Activities?
Cash from Operating Activities
8B
USD
8B
USD
Based on the financial report for Dec 31, 2023, Gilead Sciences Inc's Cash from Operating Activities amounts to 8B USD.
What is Gilead Sciences Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
10%
10%
Over the last year, the Cash from Operating Activities growth was -12%. The average annual Cash from Operating Activities growth rates for Gilead Sciences Inc have been -1% over the past three years , -1% over the past five years , and 10% over the past ten years .
You don't have any saved screeners yet
